Flecainide in children with long QT syndrome: the first experience in Russia
https://doi.org/10.35336/VA-1573
Abstract
We presented 2 clinical cases for patients with Long QT3, where we used flecainide together with beta-blocker therapy the first time in the Russian Federation in this disease.
About the Authors
V. N. Komoliatova
FSBI “FSCC for Children and Adolescents of the Federal Medical and Biological Agency of Russia” ; FSBEI of Additional Professional Education “Russian Medical Academy of Continuous Professional Education” of the MH RF
Russian Federation
Russian Federation
Komoliatova Vera
Moscow, 20 Moskvorechye str.
Moscow, 2/1 Barrikadnaya str., buil.1
L. M. Makarov
FSBI “FSCC for Children and Adolescents of the Federal Medical and Biological Agency of Russia” ; FSBEI of Additional Professional Education “Russian Medical Academy of Continuous Professional Education” of the MH RF
Russian Federation
Russian Federation
Moscow, 20 Moskvorechye str.
Moscow, 2/1 Barrikadnaya str., buil.1
I. I. Kiseleva
FSBI “FSCC for Children and Adolescents of the Federal Medical and Biological Agency of Russia”
Russian Federation
Russian Federation
Moscow, 20 Moskvorechye str.
S. R. Rodionovskaya
FSBI “FSCC for Children and Adolescents of the Federal Medical and Biological Agency of Russia” ; FSBI State Scientific Center “FMBC named after. A.I. Burnazyan FMBA of Russia”
Russian Federation
Russian Federation
Moscow, 20 Moskvorechye str.
Moscow, 23/2 Marshala Novikova str.
E. V. Kuznetsova
FSBI “FSCC for Children and Adolescents of the Federal Medical and Biological Agency of Russia”
Russian Federation
Russian Federation
Moscow, 20 Moskvorechye str.
References
1. Wilde A, Amin AS, Postema PG. Diagnosis, management and therapeutic strategies for congenital long QT syndrome. Heart. 2022;108(5): 332-338. https://doi.org/10.1136/heartjnl-2020-318259.
2. Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: An International Multicenter Study. Circulation. 2016;134: 872-882. https://doi.org/10.1161/CIRCULATIONAHA.116.021823.
3. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292: 1341- 1344. https://doi.org/10.1001/jama.292.11.1341.
4. Schwartz PJ, Priori SG, Spazzolini C, et al Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103: 89-95. https://doi.org/10.1161/01.cir.103.1.89.
5. Miura M, Yamagishi H, Morikawa Y, et al. Congenital long QT syndrome and 2:1 atrioventricular block with a mutation of the SCN5A gene. Pediatr Cardiol. 2003;24: 70-72. https://doi.org/10.1007/s00246-002-0169-5.
6. Veldkamp MW, Wilders R, Baartscheer A, et al. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res. 2003;92: 976-983. https://doi.org/10.1161/01.RES.0000069689.09869.A8.
7. Van den Berg MP, Wilde AA, Viersma TJW, et al. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12: 630-636. https://doi.org/10.1046/j.1540-8167.2001.00630.x.
8. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/ APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes/ Heart Rhythm. 2013 Dec;10(12): 1932- 63. https://doi.org/10.1016/j.hrthm.2013.05.014.
9. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92: 3381-6.
10. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67: 1053-8.
11. Bos JM, Crotti L, Rohatgi RK, et al. Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome. Circ Arrhythm Electrophysiol. 2019;12: e007280.
12. Chorin E, Taub R, Medina A, et al. Long-term flecainide therapy in type 3 long QT syndrome. Europace. 2018; 20(2): 370-376. https://doi.org/10.1093/europace/euw439.
13. Mihailov EN, Gizatullina TP, Lebadev DS. Ventricular arrhythmias and sudden death. Clinical recommendation (In Russ.).
14. Makarov LM Akopyan AG, Zaklyazminskay EV, et al. New ECG fenomen in LQT syndrome, clinical case. Pediatric for GN Speranskogo. 2024;103(5): 126-131 (In Russ.). https://doi.org/10.24110/0031-403X-2024-103-5-126-131.
15. Paolini E, Stronati G, Guerra F, et al. Flecainide: Electrophysiological properties, clinical indications, and practical aspects. Pharmacol Res. 2019;148: 104443. https://doi.org/10.1016/j.phrs.2019.104443.
16. Condori Leandro HI, Lebedev DS, Mikhaylov EN. Therapeutic potential of flecainide for cardiac arrhythmias:a short review of studies and clinical recommendations. Journal of Arrhythmology. 2024;31(3): е1-е7. (In Russ.). https://doi.org/10.35336/VA-1397.
17. Aliot E, Capucci A, Crijns HJ, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace.201;13(2): 161-73. https://doi.org/10.1093/europace/euq382.
18. Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with a new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000;101: 1698-706.
19. Rosero SZ, Zareba W, Robinson JL, et al. Gene-specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium channel gene. Ann Noninv Electrocardiol. 1997;2: 274 -278.
20. Basza M, Maciejewski C ,Bojanowicz W, et al. Flecainide in clinical practice. Cardiol J 2023;30(3): 473-482. https://doi.org/10.5603/CJ.a2023.0018.
21. Makarov LM, Komolyatova VN, Zaklyazminskaya EV, et al. 2 Cases of New Electrocardiographic Patterns in Patients With Long QT Syndrome. JACC Case Rep. 2025 Jun 18;30(15): 103753. https://doi.org/10.1016/j.jaccas.2025.103753.
Review
For citations:
Komoliatova V.N., Makarov L.M., Kiseleva I.I., Rodionovskaya S.R., Kuznetsova E.V. Flecainide in children with long QT syndrome: the first experience in Russia. Journal of Arrhythmology. 2026;33(1):68-72. https://doi.org/10.35336/VA-1573
Views:
317
JATS XML
Email this article 